MANUSCRIPT
People with type 2 diabetes mellitus, 1 prediabetes 2 and insulin resistance 3 4 are more likely to develop myocardial infarction and stroke and have also associated metabolic abnormalities, such as lipid abnormalities, hypertension and chronic vascular inflammation, that are themselves significant cardiovascular risk factors. 5 6 Pioglitazone is known to improve insulin sensitivity, glycaemic control, hypertension, dyslipidaemia and microalbuminuria in patients with diabetes mellitus. 5 Furthermore, a prior meta-analysis found that pioglitazone reduced the risk of myocardial infarction, stroke and death compared to control drugs or placebo in patients with type 2 diabetes mellitus, but whether pioglitazone is beneficial in prevention of cardiovascular diseases among patients with pre-diabetes or insulin resistance was not addressed. 7 Since then, several randomised controlled trials have been published to evaluate the effect of pioglitazone on occurrence of cardiovascular events in various types of patients. [8] [9] [10] [11] [12] [13] [14] These trials comprised patients with insulin resistance, 9 pre-diabetes (eg, impaired fasting glucose and/or impaired glucose tolerance) 8 10 or type 2 diabetes mellitus. Therefore, to qualitatively and quantitatively evaluate the overall benefits (eg, major adverse cardiovascular events, myocardial infarction and stroke) and risks (eg, heart failure, fracture, all-cause mortality, cancer,
Strengths and limitations of this study
▪ Pioglitazone reduced major adverse cardiovascular events in people with insulin resistance, prediabetes and diabetes mellitus (DM). ▪ Pioglitazone increased risks of heart failure, oedema and weight gain. ▪ Pioglitazone reduced new-onset DM in insulin resistance and pre-diabetes people. ▪ The results were dominated by two large randomised controlled trials.
bladder cancer, oedema, weight gain and hypoglycaemia) of pioglitazone therapy in patients with insulin resistance, pre-diabetes and type 2 diabetes, we conducted a systematic review and meta-analysis of relevant randomised controlled trials to date.
METHODS
The current meta-analysis was conducted in accordance with the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis: the PRISMA Statement. 15 17 May 2016) using MESH terms and free text: 'pioglitazone' or 'actos' AND 'diabetes mellitus' or 'glucose intolerance' or 'prediabetic state' or 'impaired glucose tolerance' or 'impaired fasting glucose' or 'insulin resistance'. We restricted the search to studies in humans and clinical trials using filters provided by PubMed and EMBASE. There was no language restriction. We retrieved further information by a manual search of references from recent reviews and relevant published original studies.
Search strategy

Study selection and data abstraction
Criteria for inclusion of this study were as follows: (1) the study design was a randomised controlled trial; (2) patients had the history of pre-diabetes or insulin resistance or type 2 diabetes mellitus; (3) the study included a comparison of pioglitazone with control (eg, placebo or other glucose-lowering agents); (4) total participants and the number of cardiovascular events (eg, composite of myocardial infarction and stroke, or either myocardial infarction and stroke) were reported separately for active treatment and control groups; (5) intended follow-up of at least 1 year for all participants. Any age or participants of either sex were included. All data from eligible studies were abstracted by two independent investigators (HWL and ML) according to a standard protocol. Discrepancies were resolved by discussion with a third investigator (YLW) and by referencing the original report. Recorded data variables were as follows: trial's name and first author's name, year of publication, country origin, population of participants, mean age, percentage women, baseline characteristics, duration of follow-up and number of participants and events for each group.
Study quality assessment
All the included studies were randomised controlled trials. The risk of bias (eg, selection bias, performance bias, detection bias, attrition bias and reporting bias) of the included trials was assessed by Cochrane risk-of-bias algorithm (http://www.cohchrane.org/training/cochranehandbook).
Data synthesis and analysis
Since pre-diabetes and diabetes do not confer the same risk for the different entities of cardiovascular disease, patients with insulin resistance/pre-diabetes and diabetes were analysed separately for cardiovascular outcomes. Insulin resistance was defined as a value of more than 3.0 on the homeostasis model assessment of insulin resistance (HOMA-IR) index. 9 The HOMA-IR value was calculated as the level of fasting glucose (measured in millimoles per litre) times the level of fasting insulin (measured in microunits per millilitre) divided by 22.5. The primary end points were the association of pioglitazone therapy (compared with control) with risks for major adverse cardiovascular events (MACE). The definition of MACE was non-fatal myocardial infarction, nonfatal stroke and cardiovascular death. The secondary end points were myocardial infarction and stroke. Safety outcomes were heart failure, fracture, all-cause mortality, cancer, bladder cancer, oedema, weight gain and hypoglycaemia. We also analysed the effect of pioglitazone versus placebo on development of diabetes among people with pre-diabetes or insulin resistance, but not having frank diabetes mellitus, at baseline.
Relative risk (RR) with 95% CIs was used to estimate the risk of clinical outcomes between the pioglitazone group and the control group. All analyses were based on the intention-to-treat principle. We entered number of participants with events and total number of participants in the pioglitazone and control groups. We pooled data across trials using a fixed-effects model based on Mantel-Haenszel methods. Heterogeneity was assessed by p value of χ 2 statistics and I 2 , which describes the percentage of variability in the effect estimates that is due to heterogeneity rather than to chance. Heterogeneity was considered if either the χ 2 test was significant with the p=0.10 level or the I 2 statistic was >50%. Publication bias was assessed graphically using a funnel plot and mathematically using an adjusted rank-correlation test, according to the Begg and Mazumdar method.
To evaluate whether the present meta-analysis had sufficient sample size to reach firm conclusions about the effect of interventions, trial sequential analysis (TSA) was performed for the major outcomes. 16 TSA performs accumulative meta-analysis, which creates Z curve of the summarised observed effect and the monitoring boundaries for benefit, harm and futility, and it estimates the required information size. These boundaries and analyses are adjusted to account for the amount of available evidence and to control for repeated analyses, while maintaining type I error at 5% and the power at 80%. The required information size was calculated based on the event rate observed in the comparator group and the pioglitazone group. If the Z curve of the cumulative meta-analysis crosses one of the boundaries, no further studies are required and there is sufficient evidence to support the conclusions.
This meta-analysis was analysed by Cochrane Collaboration's Review Manager Software Package (RevMan 5.3). The Begg and Egger tests and the trim-and-fill tests were conducted using Stata V.12.0. The empirical continuity correction and TSA were conducted using TSA software V.0.9 (β).
RESULTS
Literature search identified 2956 articles and 2945 were excluded by reviewing topics or abstracts. The literature review identified 11 8-14 17-20 articles for detailed assessment (see online supplementary figure 1). One study was excluded because the study period was <1 year. 18 Our final primary analysis included 10 articles derived from 9 randomised controlled trials. 8-14 17 19 20 A total of 12 026 individuals were eligible, with mean age 61.8 ±9.0 years, and of whom 36% were women. About 5997 (50%) participants were randomly assigned to the pioglitazone group and 6029 (50%) participants were randomly assigned to the control group. The baseline characteristics and design of the included trials were summarised in table 1. All enrolled individuals had a history of insulin resistance, impaired glucose tolerance test or type 2 diabetes mellitus. The studies included participants with or without prior cardiovascular diseases. Two studies (IRIS, J-SPIRIT) 9 10 enrolled only participants with a stroke or transient ischaemic attack, while in the other studies the majority of participants had not experienced a stroke or transient ischaemic attack at the time of study entry. The number of participants ranged from 121 to 5238. The mean study duration was 2.7 years (ranged from 1 to 4.8 years). The assessment of risk of bias is shown in table 2. Three trials had high risks of performance bias and detection bias because they were non-blinded. 10 11 14 Cardiovascular outcomes Among patients with pre-diabetes or insulin resistance, pioglitazone was associated with lower risks of MACE (2 trials; RR 0.77, 95% CI 0.64 to 0.93; p for heterogeneity=0.44, I
2 =0%) and myocardial infarction (2 trials; RR 0.68, 95% CI 0.49 to 0.96; p for heterogeneity=0.38, I 2 =0%). Pioglitazone was associated with a trend towards reducing recurrent stroke risk among patients with prediabetes or insulin resistance (2 trials; RR 0.81, 95% CI 0.65 to 1.01; p for heterogeneity=0.45, I 2 =0%) (figure 1). Since data were only available in two trials for each end point, publication bias could not be evaluated. TSA was conducted by using fixed effects mode and showed the number of patients evaluated MACE (n=4478), myocardial infarction (n=4478) and stroke (n=4598) did not surpass the required information sizes (n=4687 for MACE, n=7213 for myocardial infarction and n=10 398 for stroke) (figure 2).
Among patients with diabetes mellitus, pioglitazone was associated with a lower risk of MACE (5 trials; RR 0.83, 95% CI 0.72 to 0.97; p for heterogeneity=0.87, I 2 =0%). The risks of myocardial infarction (5 trials; RR 0.80, 95% CI 0.62 to 1.03; p for heterogeneity=0.78, I 2 =0%) and stroke (5 trials; RR 0.78, 95% CI 0.60 to 1.02; p for heterogeneity=0.90, I 2 =0%) were not significantly different between pioglitazone and comparator groups ( figure 3 ). There was no publication bias in end points of MACE (p=0.88), myocardial infarction (p=0.80) and stroke (p=0.06), respectively. TSA was conducted by using fixed effects mode and showed that the number of patients evaluated for MACE (n=7307), myocardial infarction (n=6841) and stroke (n=6840) did not surpass the required information sizes (n=10 578 for MACE, n=17 733 for myocardial infarction and n=16 379 for stroke; figure 4) . 
Safety outcomes
Pioglitazone, as compared to control group, was associated with increased risk of heart failure (5 trials; RR 1.32, 95% CI 1.14 to 1.54; p for heterogeneity=0.43, I 2 =0%) and bone fracture (4 trials; RR 1.52, 95% CI 1.17 to 1.99; p for heterogeneity=0.18, I 2 =39%). There was no significant difference in the rate of all-cause mortality (7 trials; RR 0.93, 95% CI 0.80 to 1.09; p for heterogeneity=0.88, I 2 =0%). Also, there was no significant difference in future any cancer (4 trials; RR 0.91, CI 0.77 to 1.08; p for heterogeneity=0.44, I
2 =0%) and bladder cancer risks (2 trials; RR 1.87, CI 0.98 to 3.57; p for heterogeneity=0.50, I 2 =0%). The Pioglitazone group had higher risk of oedema (7 trials; RR 1.63, CI 1.52 to 1.75; p for heterogeneity=0.001, I
2 =0%), weight gain (4 trials; RR 1.60, CI 1.50 to 1.72; p for heterogeneity=0.04, I 2 =64%) and hypoglycaemia (5 trials; RR 1.24, CI 1.13 to 1.35; p for heterogeneity<0.00001, I
2 =93%) ( figure 5 ). There was no publication bias in end points of heart failure ( p=0.58), bone fracture ( p=0.77), all-cause mortality ( p=0.47), any cancer ( p=0.24), oedema ( p=0.09), weight gain ( p=0.40), and hypoglycaemia ( p=0.37). TSA was conducted by using fixed effects mode and showed that the number of patients evaluated for all-cause mortality (n=11 319), any cancer (n=10 197), bladder cancer (n=9114) and hypoglycaemia (n=10 702) did not surpass the required information size (n=129 249 for all-cause mortality, n=76 738 for any cancer, n=20 346 for bladder cancer and n=183 329 for hypoglycaemia).
The rate of progression to diabetes was significantly lower in the pioglitazone group than in the placebo group among people with pre-diabetes or insulin resistance (2 trials; RR 0.40, 95% CI 0.25 to 0.65; p for heterogeneity=0.11). 8 9 
DISCUSSION
Our meta-analysis including 9 randomised controlled trials with over 120 100 participants found that adding pioglitazone to standard therapy was associated with a 23% risk reduction of MACE among patients with insulin resistance or pre-diabetes and 17% risk reduction of MACE among patients with type 2 diabetes mellitus. The results of our analysis suggest that the cardiovascular event reduction seen with pioglitazone among patients with diabetes mellitus is also seen among patients with insulin resistance or pre-diabetes. Also, pioglitazone use in people with pre-diabetes or insulin resistance, but not having frank diabetes mellitus at baseline, significantly reduced new-onset diabetes mellitus. However, pioglitazone use was associated with increased risks of heart failure, bone fracture, oedema and weight gain.
The exact mechanism underlying the cardiovascular risk reduction benefit of pioglitazone is not clear. It would seem unlikely to be simply its hypoglycaemic effect. [21] [22] [23] Since the pathogenesis of atherosclerosis is multifactorial involving dyslipidaemia, oxidation of lipoprotein and interactions of inflammatory cell, 24 it more likely that the benefit of pioglitazone in cardiovascular event risk reduction is due to its several pleiotropic effects. For instance, favourable effects of pioglitazone use on the triglyceride/high-density lipoprotein-cholesterol ratio correlated with delayed atheroma progression in patients with diabetes. 25 Also, cholesterol efflux capacity was inversely associated with the incidence of cardiovascular events in a population-based cohort 26 and treatment with pioglitazone for 12 weeks significantly increased the cholesterol efflux capacity. 27 In a study using serial (18) F-fluorodeoxyglucose positron emission tomography imaging to evaluate atherosclerotic plaque inflammation, pioglitazone attenuated atherosclerotic plaque inflammation in patients with impaired glucose tolerance or in patients with diabetes. 28 However, the observed cardiovascular benefits of pioglitazone cannot be simply explained by a thiazolidinedione 'class effect', since another agent in this class, rosiglitazone, has been associated with an increased risk of cardiovascular events in several meta-analyses. 29 30 There are several safety considerations in use of pioglitazone and we assessed safety outcomes in the present meta-analysis. Fluid retention, weight gain and heart failure are the most concerned adverse effects when patients receive thiazolidinedione compounds. In the current meta-analysis, the risk of heart failure, oedema and weight gain increased in the pioglitazone treatment group. Certain strategies such as excluding patients with a prior heart failure and using safety algorithms that triggered dose reduction for excessive oedema or weight gain may be helpful to reduce the incidence of heart failure in patients receiving pioglitazone therapy. 9 We found that pioglitazone use was associated with increased risks of bone fracture. A meta-analysis of randomised controlled trials showed that treatment with thiazolidinediones resulted in modest bone loss. 31 One study suggested thiazolidinediones increased bone fracture in women, but not in men, 32 while other studies suggest that both sexes are similarly affected. 33 However, the two included trials in our current analysis, with predominantly with men (> 60% of participants) both showed pioglitazone use substantially increased risk of bone fracture. 9 13 Peroxisome proliferator activated receptor-γ may play a role in carcinogenesis 34 and the risk of cancer is a concern when thiazolidinedione is prescribed. Several studies 35 36 and a meta-analysis 37 reported that pioglitazone increased the risk of bladder cancer while other cohort studies 38 39 did not find that pioglitazone increased the risk of bladder cancer or other common cancers. In the analysis of our included trials that had reported the incidence of any cancer, the risk of cancer in pioglitazone-treated patients was not increased. However, only a few trials reported a cancer end point in our study and the risk of cancer when using pioglitazone needs to be further clarified.
This meta-analysis suggested that pioglitazone use reduced progression to diabetes mellitus in patients with impaired glucose tolerance 8 and insulin resistance population 9 which is in consistent with findings from a prior study. 40 Since diabetes mellitus is a major cardiovascular risk factor, avoiding or delaying onset of diabetes mellitus with pioglitazone treatment probably helped to prevent the development of macrovascular complications.
There are several limitations in this study. First, this meta-analysis was not registered in PROSPERO. Second, the results of this analysis dominated by two trials: IRIS 9 and PROactive 17 trials. The original purpose in some of the included trials was not to investigate the effect of pioglitazone on cardiovascular events. Third, the definition of MACE differed among available trials. Some trials 8 9 reported composite of myocardial infarction and stroke while others 11 13 14 17 19 reported non-fatal myocardial infarction, non-fatal stroke and vascular death as major vascular events. Since fatal myocardial infarction and fatal stroke are likely the major components of cardiovascular death, the end points categorised as major cardiovascular events among available trials may not be substantially different. Fourth, the populations and frequency of medication use, especially statins, differed across trials. Since our study was a study-level meta-analysis, the issues mentioned above may not be well-settled. Individual-level pooled analyses of relevant trials could provide additional insights. Finally, TSA showed that the required information sizes were not achieved for most end points.
In summary, the current meta-analysis of completed, randomised clinical trials indicates that pioglitazone has beneficial effects in reducing the risk of MACE in people with insulin resistance, pre-diabetes and type 2 diabetes mellitus. Rates of heart failure, bone fracture, weight gain and oedema increased in pioglitazonetreated patients, while the occurrences of cancer and allcause mortality did not rise. Weighing the risk-benefit profile, treatment with pioglitazone may be a reasonable choice in appropriately selected patients with insulin resistance, pre-diabetes and type 2 diabetes mellitus.
